BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

WILMINGTON, Del.--(BUSINESS WIRE)--May 2, 2025-

Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints.

AstraZeneca’s Breztri Aerosphere Shows Positive Phase III Results for Uncontrolled Asthma Treatment

AstraZeneca’s Breztri Aerosphere Shows Positive Phase III Results for Uncontrolled Asthma Treatment (IN BRIEF) Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improves lung function in patients with uncontrolled asthma, compared to dual-combination ICS/LABA therapy. The trials demonstrate the potential of Breztri to evolve asthma t…

World Asthma Day 2025: Make Inhaled Treatments Accessible for ALL

Overview World Asthma Day is an annual event initiated by the Global Initiative for Asthma (GINA) to raise awareness, improve asthma care, and advocate for equitable access to essential treatments.… The post World Asthma Day 2025: Make Inhaled Treatments Accessible for ALL appeared first on Public Health Update.

AstraZeneca Plc Breztri succeeds in Phase III asthma trials

AstraZeneca Plc (LON:AZN) has confirmed that Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma. Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically signific…

AstraZeneca’s ‘smoker’s lung’ therapy meets main goals of late-stage asthma trials - Regional Media News

(Reuters) -AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma, showing clinically meaningful improvement in lung function. The Anglo-Swedish drugmaker’s therapy, already approved for the treatment of Chronic Obstructive Pulmonary Disease or “smoker’s lung”, was being compared with a dual-combination maintenance treatment in the trials. The results come …